Table 1. Summary of the coronavirus disease 2019 vaccines introduced in the Republic of Korea.

Manufacturer	Platform	Doses	Progress	Time of introduction in Korea4	Contracted doses	Overall Efficacy	Efficacy in United Kingdom (B.1.1.7 as dominant variant)	Efficacy in South Africa (B.1.351 as dominant variant)
Pfizer/BioNtech	mRNA	2	Currently in use	February 2021 (COVAX facility)	20 million doses (for 10 million people)	95%5	No biologically significant difference from previous variants9	Not available
				3rd quarter of 2021 (government contract)
Moderna	mRNA	2	Currently in use	2nd quarter of 2021	40 million doses (for 20 million people)	94%6	No significant impact of neutralizing titers against B.1.1.710	6-fold reduction in neutralizing titers was observed against the B.1.351 variant10
Astra Zeneca	Adenovirus-vector	2	Currently in use	February 2021	20 million doses (for 10 million people)	62%a11	74.6%13	Limited efficacy against mild disease14
						82%b12
JNJ	Adenovirus-vector	1	Phase 3 clinical trial completed (interim)	2nd quarter of 2021	6 million doses (for 6 million people)	66%c7	86%d	57%
Novavax	Protein subunit	2	Phase 3 clinical trial completed (interim)	Contract in progress	40 million doses (for 20 million people)	89%8	89%	60% (HIV-negative population)
								49% (including HIV-positive population)

HIV = human immunodeficiency virus.

^aWith standard dose; ^bA longer prime-boost interval; ^cFor moderate to severe disease prevention; ^dPost-hoc analysis in the United States.